MNG413
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.441
- OXIDATIVE_PHOSPHORYLATION+0.430
- TNFA_SIGNALING_VIA_NFKB+0.407
- HYPOXIA+0.393
- P53_PATHWAY+0.316
- MYOGENESIS+0.294
- APICAL_SURFACE+0.285
- UV_RESPONSE_UP+0.277
- ESTROGEN_RESPONSE_EARLY+0.250
- ADIPOGENESIS+0.247
Top 10 suppressed
- PROTEIN_SECRETION-0.404
- UV_RESPONSE_DN-0.311
- ANDROGEN_RESPONSE-0.293
- MITOTIC_SPINDLE-0.289
- E2F_TARGETS-0.284
- G2M_CHECKPOINT-0.253
- TGF_BETA_SIGNALING-0.215
- INTERFERON_ALPHA_RESPONSE-0.138
- PI3K_AKT_MTOR_SIGNALING-0.106
- SPERMATOGENESIS-0.081
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 9a4f9e4a-dc97-4f8d-9075-537b62fb98d3 | — | — | 0.809 |
| 2 | 131e315e-6653-4199-b653-42b81644dad9 | — | — | 0.808 |
| 3 | SRR1465917 | GTEX | — | 0.806 |
| 4 | MNG610 | — | — | 0.798 |
| 5 | 09f758e5-6be1-4f29-ac92-869d92f8fbcf | — | — | 0.791 |
| 6 | MNG589 | — | — | 0.781 |
| 7 | MNG1090 | — | — | 0.772 |
| 8 | TCGA-85-A4JC-01A-11R-A24Z-07 | — | cohortSQ1 | 0.754 |
| 9 | MDT-AP-2382 | Med | Medulloblastoma | 0.753 |
| 10 | R74 | — | — | 0.748 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.441 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.430 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.407 | Inavolisib | — uncovered |
| HYPOXIA | 0.393 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.316 | Idelalisib | — uncovered |
| MYOGENESIS | 0.294 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.285 | Temsirolimus | — uncovered |
| UV_RESPONSE_UP | 0.277 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.250 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.247 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.222 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.205 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.182 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.177 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.170 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.161 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.156 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.151 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.127 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.122 | Remibrutinib | — uncovered |